Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/16/2023 | $140.00 → $175.00 | In-line → Outperform | Evercore ISI |
| 2/16/2023 | $155.00 → $175.00 | Outperform → Strong Buy | Raymond James |
| 2/6/2023 | $162.00 → $141.00 | Outperform → Market Perform | SVB Securities |
| 11/21/2022 | $135.00 | Hold | Truist |
| 10/11/2022 | $177.00 → $178.00 | Market Perform → Outperform | BMO Capital Markets |
| 6/29/2022 | $220.00 | Outperform | Raymond James |
| 6/24/2022 | $169.00 | Market Perform | BMO Capital Markets |
| 2/16/2022 | $201.00 → $142.00 | Market Outperform | JMP Securities |
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR) Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ:SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, fo
NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i